Patrick Gan Elected to Inovio Biomedical Board of Directors

Share Article

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today that Patrick Gan was elected as the Company's eighth director at Inovio's annual general meeting. He joins re-elected directors James L. Heppell, chairman of the board, Dr. Avtar Dhillon, president and CEO, and Riaz Bandali, Simon X. Benito, Tazdin Esmail, Robert W. Rieder and Stephen Rietiker, MD.

News Image
Patrick Gan brings to Inovio's board of directors extensive pharmaceutical operating experience, with an emphasis on the fast-growing Asia market

    Mr. Gan has extensive senior management experience with pharmaceutical operations throughout Asia and is currently the managing partner of ATP Capital, a global biotech fund. He has previously been the Asia/Pacific area director for Novartis, managing director for Glaxo Wellcome in China and Taiwan, and a senior manager with Roche. He has also been chief executive of two regional Asian airlines, Tiger Airways and Jett Air Cargo. He received an honors degree in Pharmacy (BSc) at the National University of Singapore in 1982, and subsequently obtained an MBA from the University of Warwick in 1990. He has also attended executive programs at Harvard Business School and Duke University.

"Patrick Gan brings to Inovio's board of directors extensive pharmaceutical operating experience, with an emphasis on the fast-growing Asia market," said Dr. Avtar Dhillon, Inovio's president & CEO. "We appreciate ATP's continued support as a shareholder of Inovio and welcome Patrick's contributions to the Board."

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2007 and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bernie Hertel
Visit website